NLS Pharmaceutics AG has announced a significant milestone in collaboration with Kadimastem Ltd. and iTolerance, Inc., as the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD Foundation) approved a new milestone-based funding payment. The grant of approximately NIS 564,400 ($166,000 USD) is part of a larger support package totaling nearly NIS 3 million ($882,352 USD) to date. This funding is allocated to advance the development of iTOL-102, a novel cell therapy aimed at curing Type 1 diabetes without the need for life-long immunosuppression. The approval follows a successful Pre-IND meeting with the U.S. FDA, paving the way for First-in-Human clinical trials. The collaboration highlights the significant scientific progress and strategic partnership between NLS Pharmaceutics, Kadimastem, and iTolerance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.